Literature DB >> 9261280

Metabolic basis of hypotriglyceridemic effects of insulin in normal men.

R Malmström1, C J Packard, T D Watson, S Rannikko, M Caslake, D Bedford, P Stewart, H Yki-Järvinen, J Shepherd, M R Taskinen.   

Abstract

The mechanism by which acute insulin administration alters VLDL apolipoprotein (apo) B subclass metabolism and thus plasma triglyceride concentration was evaluated in 7 normolipidemic healthy men on two occasions, during a saline infusion and during an 8.5-hour euglycemic hyperinsulinemic clamp (serum insulin, 490 +/- 30 pmol/L). During the insulin infusion, plasma triglycerides decreased by 22% (P < .05), and serum free fatty acid decreased by 85% (P < .05). The plasma concentration of VLDL1 apo B fell 32% during the insulin infusion, while that of VLDL2 apo B remained constant. A bolus injection of [3-(2)H]leucine was given on both occasions to trace apo B kinetics in the VLDL1 and VLDL2 subclasses (Svedberg flotation rate, 60-400 and 20-60, respectively), and the kinetic basis for the change in VLDL levels caused by insulin was examined using a non-steady-state multicompartmental model. The mean rate of VLDL1 apo B synthesis decreased significantly by 35% (P < .05) after 0.5 hour of the insulin infusion (523 +/- 87 mg/d) compared with the saline infusion (808 +/- 91 mg/d). This parameter was allowed to vary with time to explain the fall in VLDL1 concentration. After 8.5 hours of hyperinsulinemia, the rate of VLDL1 apo B synthesis was 51% lower (321 +/- 105 mg/d) than during the saline infusion (651 +/- 81 mg/d, P < .05). VLDL2 apo B production was similar during the saline (269 +/- 35 mg/d) and insulin (265 +/- 37 mg/d) infusions. No significant changes were observed in the fractional catabolic rates of either VLDL1 or VLDL2 apo B. We conclude that acute hyperinsulinemia lowers plasma triglyceride and VLDL levels principally by suppressing VLDL1 apo B production but has no effect on VLDL2 apo B production. These findings indicate that the rates of VLDL1 and VLDL2 apo B production in the liver are independently regulated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9261280     DOI: 10.1161/01.atv.17.7.1454

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  33 in total

1.  Impaired-inactivation of FoxO1 contributes to glucose-mediated increases in serum very low-density lipoprotein.

Authors:  Ke Wu; David Cappel; Melissa Martinez; John M Stafford
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

Review 2.  Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments.

Authors:  Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2006-09-01       Impact factor: 5.922

3.  The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.

Authors:  G D Tan; B A Fielding; J M Currie; S M Humphreys; M Désage; K N Frayn; M Laville; H Vidal; F Karpe
Journal:  Diabetologia       Date:  2004-12-24       Impact factor: 10.122

4.  Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat.

Authors:  Chunyu Zheng; Katsunori Ikewaki; Brian W Walsh; Frank M Sacks
Journal:  J Lipid Res       Date:  2006-05-09       Impact factor: 5.922

5.  Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size.

Authors:  Daniël B van Schalkwijk; Albert A de Graaf; Ben van Ommen; Kees van Bochove; Patrick C N Rensen; Louis M Havekes; Niek C A van de Pas; Huub C J Hoefsloot; Jan van der Greef; Andreas P Freidig
Journal:  J Lipid Res       Date:  2009-06-10       Impact factor: 5.922

6.  Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations.

Authors:  A Kotronen; V R Velagapudi; L Yetukuri; J Westerbacka; R Bergholm; K Ekroos; J Makkonen; M-R Taskinen; M Oresic; H Yki-Järvinen
Journal:  Diabetologia       Date:  2009-02-13       Impact factor: 10.122

7.  Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids.

Authors:  Mirjana Pavlic; Changting Xiao; Linda Szeto; Bruce W Patterson; Gary F Lewis
Journal:  Diabetes       Date:  2009-12-22       Impact factor: 9.461

Review 8.  Diabetic dyslipidaemia: from basic research to clinical practice.

Authors:  M-R Taskinen
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

9.  Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome.

Authors:  A Kotronen; A Seppälä-Lindroos; R Bergholm; H Yki-Järvinen
Journal:  Diabetologia       Date:  2007-11-16       Impact factor: 10.122

10.  Transient massive hyperlipidaemia in a type 2 diabetic subject.

Authors:  G B Vigna; A Passaro; K Bonomo; G Anfossi; R Fellin; M Trovati
Journal:  Intern Emerg Med       Date:  2007-03-31       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.